Faron Pharmaceuticals
1,72
EUR
-1,38 %
FARON
First North Finland
Biotechnology & Pharmaceuticals
Health Care
4.921 investorer følger denne virksomhed
-1,38%
-10,14%
-31,75%
-14,21%
-44,52%
-54,38%
-44,52%
-56,4%
-
-50,57%
www.faron.com/investors
Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.
Læs mereP/E (adj.) (24e)
-6,05
EV/EBIT (adj.) (24e)
-7,05
P/B (24e)
-17,61
Udbytteafkast, % (24e)
-
Kursmål
2.80 EUR
Anbefaling
Akkumulér
Opdateret
28.8.2024
First North Finland
FARON
Daglig lav / høj pris
1,72 / 1,782
EUR
Markedsværdi
179,95 mio. EUR
Aktieomsætning
22,17 t EUR
Volumen
13 t
Business risk
Valuation risk
Current
Previous
Seneste analyser
Extensive report
Inderes' extensive report is an investor's handbook on customer companies covered by our research.
The latest extensive report was released
Read the reportAnalytiker
Antti Siltanen
Analytiker
Resultatopgørelse
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| Omsætning | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 | 3,4 |
| vækst-% | 86.030,6 % | |||||||
| EBITDA | -16,4 | -20,8 | -27,4 | -28,2 | -25,7 | -29,0 | -30,3 | -27,6 |
| EBIT (adj.) | -16,7 | -21,1 | -27,4 | -28,6 | -26,1 | -29,2 | -30,5 | -27,8 |
| EBIT | -16,7 | -21,1 | -27,4 | -28,6 | -26,1 | -29,2 | -30,5 | -27,8 |
| Overskud før skat | -16,9 | -21,2 | -28,7 | -30,9 | -29,7 | -31,2 | -32,7 | -30,2 |
| Netto indkomst | -16,9 | -21,2 | -28,6 | -30,9 | -29,7 | -31,2 | -32,7 | -30,2 |
| EPS (adj.) | -0,36 | -0,40 | -0,48 | -0,45 | -0,28 | -0,30 | -0,31 | -0,29 |
| vækst-% | ||||||||
| Udbytte | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
| Udbytte ratio |
Lønsomhed og afkast på kapital
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| EBITDA-% | -409.275,0 % | -520.050,0 % | -685.675,0 % | -705.550,0 % | -643.250,0 % | -725.782,5 % | -758.350,0 % | -801,6 % |
| EBIT-% (adj.) | -416.350,0 % | -527.700,0 % | -685.650,0 % | -714.200,0 % | -653.250,0 % | -730.500,0 % | -762.390,0 % | -805,6 % |
| EBIT-% | -416.350,0 % | -527.700,0 % | -685.650,0 % | -714.200,0 % | -653.250,0 % | -730.500,0 % | -762.390,0 % | -805,6 % |
| ROE | 14.063,1 % | -3.920,3 % | 670,4 % | 232,3 % | 234,3 % | 120,9 % | 56,6 % | 33,8 % |
| ROI | -676,3 % | -588,9 % | -707,3 % | 7.250,8 % | 3.960,6 % | -3.336,9 % | -4.042,5 % | -4.212,1 % |
Værdiansættelse
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| Aktiekurs (EUR) | 2,91 | 3,24 | 3,71 | 3,77 | 1,72 | 1,72 | 1,72 | 1,72 |
| Aktier | 46,9 | 53,2 | 59,8 | 68,8 | 104,6 | 104,6 | 104,6 | 104,6 |
| Markedsværdi | 136,5 | 172,5 | 221,6 | 259,3 | 180,0 | 180,0 | 180,0 | 180,0 |
| Enterprise value | 135,1 | 169,0 | 227,5 | 265,3 | 184,1 | 215,2 | 247,8 | 277,9 |
| EV/S | 33.775,4 | 42.241,4 | 56.880,5 | 66.337,2 | 46.029,4 | 53.800,5 | 61.947,7 | 80,7 |
| EV/EBITDA | - | - | - | - | - | - | - | - |
| EV/EBIT (adj.) | - | - | - | - | - | - | - | - |
| EV/EBIT | - | - | - | - | - | - | - | - |
| P/E (adj.) | - | - | - | - | - | - | - | - |
| P/E | - | - | - | - | - | - | - | - |
| P/B | - | 58,8 | - | - | - | - | - | - |
| P/S | 34.117,3 | 43.117,9 | 55.389,8 | 64.831,5 | 44.988,3 | 44.988,3 | 44.988,3 | 52,2 |
| Udbytteprocent | ||||||||
| Equity ratio | -22,1 % | 22,3 % | -101,8 % | -148,4 % | -97,9 % | -402,0 % | -726,8 % | -1.031,1 % |
| Gearing ratio | 73,9 % | -119,5 % | -52,0 % | -39,7 % | -40,7 % | -85,1 % | -91,5 % | -93,9 % |
Kvartalsdata
| Q3/23 | Q4/23 | 2023 | Q1/24 | Q2/24 | Q3/24e | Q4/24e | 2024e | Q1/25e | |
|---|---|---|---|---|---|---|---|---|---|
| Omsætning | 0,0 | 0,0 | 0,0 | 0,0 | |||||
| EBITDA | -15,6 | -28,2 | -11,1 | -14,6 | -25,7 | ||||
| EBIT | -15,8 | -28,6 | -11,3 | -14,8 | -26,1 | ||||
| Overskud før skat | -17,2 | -30,9 | -14,4 | -15,3 | -29,7 | ||||
| Netto indkomst | -17,2 | -30,9 | -14,4 | -15,3 | -29,7 |
ViserAlle indholdstyper
Faron Pharmaceuticals Oy: Composition of Faron Pharmaceutical's Shareholders' Nomination Board
Faron Pharmaceuticals Capital Markets Day 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Faron Pharmaceuticals Oy: Faron's Capital Markets Day 2024
Faron Pharmaceuticals Oy: Faron announces Capital Markets Day
Probabilities of success in drug development
Clinical phases of drug development
Faron Pharmaceuticals Oy: Grant of options
Faron Pharmaceuticals, Q2'24
Redeye: Faron Pharmaceuticals H1 - Turbulent times behind, promising times ahead
Faron Pharmaceuticals Oy: Faron 2024 Half-Year Financial Results
Faron Pharmaceuticals Oy: FDA Grants Fast Track Designation for Bexmarilimab
Faron Pharmaceuticals Oy: Notice of Half-Year Financial Results
Faron Pharmaceuticals Oy: Traumakine Research Collaboration and DoD Grant
Faron Pharmaceuticals Oy: Appointment of Chief Financial Officer
Faron Pharmaceuticals Oy: Grant of options
Faron Pharmaceuticals Oy: Faron Appoints Dr. Petri Bono as new CMO
